A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN 001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (HV(s) and Participants With Thyroid Eye Disease (TED)
Latest Information Update: 12 Jul 2024
At a glance
- Drugs Veligrotug (Primary)
- Indications Graves ophthalmopathy
- Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
- Acronyms THRIVE
- Sponsors Viridian Therapeutics
- 07 May 2024 Status changed from recruiting to active, no longer recruiting.
- 07 Sep 2023 Planned End Date changed from 1 May 2025 to 1 Mar 2025.
- 07 Sep 2023 Planned primary completion date changed from 1 Mar 2025 to 1 Jul 2024.